MA49960A - Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes de traitement de sujets souffrant d'un syndrome hémolytique atypique - Google Patents

Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes de traitement de sujets souffrant d'un syndrome hémolytique atypique

Info

Publication number
MA49960A
MA49960A MA049960A MA49960A MA49960A MA 49960 A MA49960 A MA 49960A MA 049960 A MA049960 A MA 049960A MA 49960 A MA49960 A MA 49960A MA 49960 A MA49960 A MA 49960A
Authority
MA
Morocco
Prior art keywords
kits
subjects
treatment
methods
low viscosity
Prior art date
Application number
MA049960A
Other languages
English (en)
Inventor
Gregory A Demopulos
Kenneth M Ferguson
William Joseph Lambert
John Steven Whitaker
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MA49960A publication Critical patent/MA49960A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MA049960A 2017-08-25 2018-08-21 Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes de traitement de sujets souffrant d'un syndrome hémolytique atypique MA49960A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762550328P 2017-08-25 2017-08-25

Publications (1)

Publication Number Publication Date
MA49960A true MA49960A (fr) 2021-06-02

Family

ID=65436837

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049960A MA49960A (fr) 2017-08-25 2018-08-21 Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes de traitement de sujets souffrant d'un syndrome hémolytique atypique

Country Status (15)

Country Link
US (2) US20190062455A1 (fr)
EP (1) EP3672994A4 (fr)
JP (1) JP2020531523A (fr)
KR (1) KR20200037863A (fr)
CN (1) CN111278863A (fr)
AU (1) AU2018322032A1 (fr)
BR (1) BR112020003632A2 (fr)
CA (1) CA3072913A1 (fr)
CL (1) CL2020000397A1 (fr)
IL (1) IL272673B2 (fr)
MA (1) MA49960A (fr)
MX (1) MX2020002077A (fr)
RU (1) RU2020111574A (fr)
TW (1) TW201925224A (fr)
WO (1) WO2019040453A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022026914A1 (fr) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Formulations d'anticorps anti-connexine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2704742B1 (fr) * 2011-05-02 2017-07-12 Millennium Pharmaceuticals, Inc. Formulation pour un anticorps anti- 4 7
CA3131223C (fr) * 2011-05-04 2024-01-30 Omeros Corporation Compositions pour inhiber l'activation de complement dependant de masp-2
EP3058951A1 (fr) * 2012-06-18 2016-08-24 Omeros Corporation Compositions et procédés d'inhibition de masp-1 et/ou masp-2 et/ou masp-3 pour le traitement de diverses maladies et troubles
SI3057993T1 (sl) * 2013-10-17 2021-03-31 Omeros Corporation Postopki za zdravljenje bolezenskih stanj, povezanih z aktivacijo komplementov, odvisnih od MASP-2
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
SG10202011469UA (en) * 2015-11-09 2020-12-30 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق

Also Published As

Publication number Publication date
AU2018322032A1 (en) 2020-03-12
IL272673B1 (en) 2024-06-01
RU2020111574A (ru) 2021-09-27
CN111278863A (zh) 2020-06-12
TW201925224A (zh) 2019-07-01
BR112020003632A2 (pt) 2020-10-27
US20240247078A1 (en) 2024-07-25
EP3672994A4 (fr) 2021-06-02
CL2020000397A1 (es) 2020-07-10
JP2020531523A (ja) 2020-11-05
MX2020002077A (es) 2020-03-24
IL272673B2 (en) 2024-10-01
CA3072913A1 (fr) 2019-02-28
EP3672994A1 (fr) 2020-07-01
WO2019040453A1 (fr) 2019-02-28
US20190062455A1 (en) 2019-02-28
RU2020111574A3 (fr) 2021-11-17
IL272673A (en) 2020-03-31
KR20200037863A (ko) 2020-04-09

Similar Documents

Publication Publication Date Title
MA46109A (fr) Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes
CY1124013T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
CO2021004456A2 (es) Vacunas neumocócicas multivalentes
JP2018172409A5 (ja) １５−ｈｅｐｅを含む組成物および同組成物を使用する方法
CR20190271A (es) Anticuerpos antitau y métodos de uso
DK3641753T3 (da) Bacitracin og/eller daptomycin kombineret med cannabidiol til behandling af bakterieinfektioner
MA43982A (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
DK3687513T3 (da) Behandling af fragilt x-syndrom og autisme med cannabidiol
MA46620A (fr) Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
CY1124286T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
MA45987A (fr) Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation
DK3697405T3 (da) Ny mek-inhibitor til behandlingen af virale og bakterielle infektioner
DK3906016T3 (da) Flydende propolisekstrakt, formulering og anvendelser deraf
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello
IT201700025666A1 (it) Composizione per l’uso nel trattamento dell’ipercolesterolemia e nella prevenzione di patologie cardiovascolari.
EA201690594A1 (ru) Состав для лечения вич-инфекции на основе атазанавира и кобицистата
MA49960A (fr) Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes de traitement de sujets souffrant d'un syndrome hémolytique atypique
MA48743A (fr) Composés et méthodes de traitement d'infections bactériennes
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
CO2019014647A2 (es) Composiciones inmunogénicas